SCHEMBL8318869

SCHEMBL8318869

Cc1cc2c(s1)-n1c(C)nnc1N(Cc1ccc(Cl)cc1)N=C2c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 4/20 0.47
LMNA P02545 3/20 0.39
OPRK1 P41145 2/20 0.39
GABRA1 P14867 1/20 0.39
HPGD P15428 1/20 0.39
CNR1 P21554 1/20 0.39
GABRA5 P31644 1/20 0.39
GABRA3 P34903 1/20 0.39
GABRA2 P47869 1/20 0.39
GABRB2 P47870 1/20 0.39
ALDH1A1 P00352 1/20 0.36
POLB P06746 1/20 0.36
PDE4D Q08499 1/20 0.36
PTAFR P25105 9/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HSD11B1 P28845 1/20 0.35
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
STAT3 P40763 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8317642 0.90 OXTR (0.40) BRD4LMNAHPGDALDH1A1SMN1; SMN2
SCHEMBL8317069 0.90 BRD4 (0.41) BRD4LMNAOPRK1GABRA1HPGD
SCHEMBL21847182 0.89 BRD4 (0.41) BRD4LMNASMN1; SMN2BRD2
SCHEMBL8315565 0.88 BRD4 (0.38) BRD4PTAFRMAPT
SCHEMBL8317576 0.87 BRD4 (0.39) BRD4LMNAOPRK1GABRA1HPGD
SCHEMBL8318376 0.86 P2RX7 (0.39) BRD4PTAFR
SCHEMBL8319973 0.86 BRD4 (0.39) BRD4OPRK1ALDH1A1PDE4DPTAFR
SCHEMBL8322696 0.86 BRD4 (0.39) BRD4OPRK1PDE4DPTAFRSMN1; SMN2
SCHEMBL21847275 0.85 BRD4 (0.34) BRD4ALDH1A1POLB
SCHEMBL8320709 0.85 BRD4 (0.36) BRD4OPRK1PDE4DPTAFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US claimed
EP-3640253-A1 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE AYUMI Pharmaceutical Corporation (JP) 2020-04-22 EP claimed
EP-0934940-A1 CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF Japan Tobacco Inc. (JP) 1999-08-11 EP claimed
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-11-30 US disclosed
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE AYUMI PHARMACEUTICAL CORPORATION (JP) 2021-05-06 US disclosed
EP-3640253-A1 6H-THIENO[2,3-E][1,2,4]TRIAZOLO[3,4-C][1,2,4]TRIAZEPINE DERIVATIVE AYUMI Pharmaceutical Corporation (JP) 2020-04-22 EP disclosed
EP-0934940-A1 CYTOKINE PRODUCTION INHIBITORS, TRIAZEPINE COMPOUNDS, AND INTERMEDIATES THEREOF Japan Tobacco Inc. (JP) 1999-08-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210130367-A1 6H-THIENO[2,3-e][1,2,4]TRIAZOLO[3,4-c][1,2,4]TRIAZEPINE DERIVATIVE BRD4, BRD3, BRD2 BRD4 1/4885LMNA 2211/4885OPRK1 1119/4885
US-11186588-B2 6H-thieno[2,3-e][1,2,4]triazolo[3,4-c][1,2,4]triazepine derivative BRD4, BRD3, BRD2 BRD4 1/4885LMNA 2211/4885OPRK1 1119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.